Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Erasca, Inc.

NASDAQ: ERAS · Life Sciences · 3 alerts · CIK 1761918

Share price
$15.11Close, Nov 16
Market cap
$5.3B
Shares outstanding
350.96MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Erasca, Inc. filings on SEC EDGAR ↗

4:09 PM ET 8-K
Financial Results

Erasca Financial Results

Erasca reported third quarter 2026 financial results, highlighting a strong cash position of $948 million following an upsized $632.5 million public offering in July. The company received FDA Fast Track Designation for ERAS-0015 in metastatic pancreatic adenocarcinoma and is preparing to initiate three potentially registration-enabling trials in pancreatic and lung cancers starting in 2027.

Term
Q3 2026

“The emerging clinical profile of ERAS-0015 continues to support its potential as a foundational therapy across RAS-mutant cancers, both as a monotherapy and backbone for combination regimens.”

Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder

“With a strengthened balance sheet and experienced R&D leadership, we believe that we are positioned to execute our near-term milestones and advance programs addressing high unmet needs for patients with RAS-mutant cancers.”

Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder
4:04 PM ET 10-Q
Financial Results

Erasca Q3 2026 Results: Net Loss of $51.3M, Loss Widens

Erasca, Inc. reported a significant increase in net loss to $278.9 million for the nine months ended September 30, 2026, primarily driven by a $150.0 million in-process research and development charge. Despite the loss, the company strengthened its balance sheet through underwritten offerings, ending the period with $947.8 million in cash, cash equivalents, and marketable securities.

Key figure
Net loss $51.3M
9:00 AM ET 8-K
Leadership Change

Erasca Leadership Change

Erasca, Inc. announced that Nicholas (Nik) Chetwyn, Ph.D., will step down as Chief Operating Officer effective November 2, 2026. The departure is part of a leadership realignment to streamline the company's reporting structure as it focuses on its RAS-targeting programs.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.